---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009221"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:30:00.885928+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat

## Summary
- Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.
- Net loss $44.1M for FY 2022 vs $51.6M in FY 2021; R&D spend $31.5M, G&A $14.5M.
- Met with FDA in Q4 2022; filed for Orphan Drug Designation for zagociguat in MELAS.
- Refined Phase 2b design for zagociguat; manufactured drug product to support the study.
- Company actively evaluating capital, capabilities, or transactions to advance pipeline and maximize value.

## SEC filing metadata
- accession: 0000950170-23-009221
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/0000950170-23-009221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/cycn-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009221
- JSON: https://secwatch.observer/filing/0000950170-23-009221.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009221.txt

## Key facts
- Earnings Releases
  Cyclerion Therapeutics, Inc. reported the full year 2022 results: net income approximately $44.1 million.
  - Period: the full year 2022
  - Net income: approximately $44.1 million
  - Result: reported results
  source text: Net loss was approximately $44.1 million for the full year 2022, as compared to $51.6 million for the full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/0000950170-23-009221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.